Vaxcell-Bio Therapeutics Logo

Vaxcell-Bio Therapeutics

Biotech firm developing immunotherapies for oncology and other diseases.

323990 | KO

Overview

Corporate Details

ISIN(s):
KR7323990002
LEI:
Country:
South Korea
Address:
전라남도 화순군 화순읍 산단길 12-55, 화순군

Description

Vaxcell-Bio Therapeutics is a biotechnology company specializing in the research and development of innovative immunotherapies. The company's primary focus is on oncology, developing a pipeline of cell-based and protein-based treatments, including immune cell therapies and targeted protein-degrading therapeutics. In addition to its core focus on cancer, Vaxcell-Bio is expanding its research into other areas, such as developing drug delivery system (DDS)-based therapies for conditions like macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2023-09-04 00:00
[기재정정]증권신고서(지분증권) (2023.10)
Korean HTML 1.9 MB
2023-08-21 00:00
[기재정정]증권신고서(지분증권) (2023.10)
Korean HTML 2.2 MB
2023-08-14 00:00
반기보고서 (2023.06)
Korean HTML 865.9 KB
2023-08-07 00:00
주권매매거래정지(무상증자)
Korean HTML 4.7 KB
2023-08-07 00:00
주요사항보고서(유무상증자결정)
Korean HTML 40.5 KB
2023-08-07 00:00
증권신고서(지분증권) (2023.10)
Korean HTML 1.6 MB
2023-07-31 00:00
투자판단관련주요경영사항(임상시험계획변경승인신청)(진행성 췌장암 환자에서 자연살해세포와 mFOLFIRINOX 병합치료의 임상 2a상 연구)
Korean HTML 11.1 KB
2023-05-12 00:00
분기보고서 (2023.03)
Korean HTML 682.8 KB
2023-03-24 00:00
정기주주총회결과
Korean HTML 19.2 KB
2023-03-15 00:00
감사보고서제출
Korean HTML 18.0 KB
2023-03-15 00:00
사업보고서 (2022.12)
Korean HTML 911.5 KB
2023-03-13 00:00
[기재정정]주주총회소집공고
Korean HTML 96.2 KB
2023-03-08 00:00
주주총회소집결의
Korean HTML 6.8 KB
2023-03-08 00:00
주주총회소집공고
Korean HTML 70.9 KB
2023-03-08 00:00
주주총회집중일개최사유신고
Korean HTML 4.7 KB

Automate Your Workflow. Get a real-time feed of all Vaxcell-Bio Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vaxcell-Bio Therapeutics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vaxcell-Bio Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.